01
Cellogen Therapeutics Raises ₹20 Crore From Kotak Alts to Build an Indigenous CAR-T Cell Therapy Supply Chain
The core investment thesis behind this ₹20 crore round centers entirely on solving a severe pricing bottleneck in modern oncology. Globally, advanced CAR-T cell therapies—which involve extracting a patient’s T-cells, gen…